Innate Pharma S.A.
IPHYF
$1.50
$0.139.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -55.81M | -52.78M | -50.09M | -51.31M | -53.52M |
| Total Depreciation and Amortization | 1.56M | 1.62M | 1.70M | 1.91M | 2.16M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.35M | 5.90M | 5.46M | 3.42M | 1.54M |
| Change in Net Operating Assets | -11.37M | -6.73M | -1.90M | 20.46M | 42.35M |
| Cash from Operations | -59.27M | -52.00M | -44.84M | -25.52M | -7.47M |
| Capital Expenditure | -159.00K | -168.90K | -180.40K | -299.80K | -422.90K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 8.15M | 12.39M | 16.76M | 13.42M | 10.38M |
| Cash from Investing | 7.99M | 12.22M | 16.58M | 13.12M | 9.96M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.91M | -8.94M | -8.97M | -8.95M | -8.94M |
| Issuance of Common Stock | 14.98M | 16.37M | 17.77M | 10.35M | 2.93M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.32M | 7.99M | 9.64M | 1.36M | -6.50M |
| Foreign Exchange rate Adjustments | 1.20M | 1.03M | 849.10K | 130.90K | -546.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.76M | -30.77M | -17.77M | -10.90M | -4.56M |